Dr. Tendulkar Discusses Post-Prostatectomy Radiation Therapy

Rahul Tendulkar, MD
Published: Tuesday, Jan 17, 2017



Rahul Tendulkar, MD, associate staff, Radiation Oncology, Cleveland Clinic, discusses post-prostatectomy radiation therapy and its impact on reducing prostate cancer mortality.

In a study on monitoring prostate-specific antigen (PSA) levels, it was revealed that men who had radical prostatectomy with high-risk features will have recurrence up to 50% post-op. Tendulkar observed that as the PSA goes up, the risk of mortality also goes up.

Patients at higher risk for PSA recurrence are those with a high Gleason score, as well as those that have positive margins. Monitoring these patients closely after surgery is key, says Tendulkar, as it helps physicians refer the patient to the appropriate radiation oncologist to go over treatment options.

Earlier intervention, side effect management, and careful monitoring by blood test have been shown to make a difference in detecting recurrence.

The key finding from this study is that there is a varying spectrum of prostate cancer, with some patients that require very aggressive treatment, so this is an important step in individualizing that treatment.
 


Rahul Tendulkar, MD, associate staff, Radiation Oncology, Cleveland Clinic, discusses post-prostatectomy radiation therapy and its impact on reducing prostate cancer mortality.

In a study on monitoring prostate-specific antigen (PSA) levels, it was revealed that men who had radical prostatectomy with high-risk features will have recurrence up to 50% post-op. Tendulkar observed that as the PSA goes up, the risk of mortality also goes up.

Patients at higher risk for PSA recurrence are those with a high Gleason score, as well as those that have positive margins. Monitoring these patients closely after surgery is key, says Tendulkar, as it helps physicians refer the patient to the appropriate radiation oncologist to go over treatment options.

Earlier intervention, side effect management, and careful monitoring by blood test have been shown to make a difference in detecting recurrence.

The key finding from this study is that there is a varying spectrum of prostate cancer, with some patients that require very aggressive treatment, so this is an important step in individualizing that treatment.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x